- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01733121
NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Tardive Dyskinesia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 2, randomized, double-blind, placebo-controlled, dose-titration study to evaluate the efficacy, safety, and tolerability of NBI-98854 (titrated to subject's optimal dose in the range of 25 to 75 mg) compared to placebo, administered once daily (q.d.) for a total of 6 weeks of treatment. Approximately 90 medically stable male and female subjects with one of the following clinical diagnoses will be enrolled: schizophrenia or schizoaffective disorder with neuroleptic-induced TD; mood disorder with neuroleptic-induced TD; or gastrointestinal disorder with metoclopramide-induced TD.
For subjects randomized to active treatment, the starting dose will be 25 mg NBI 98854, which may be escalated in increments of 25 mg every 2 weeks to a maximum of 75 mg to achieve an optimal dose of NBI-98854 for each subject
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Caguas, Puerto Rico, 00725
-
-
-
-
California
-
Costa Mesa, California, United States, 92626
-
Fountain Valley, California, United States, 92708
-
Oceanside, California, United States, 92056
-
-
Colorado
-
Englewood, Colorado, United States, 80113
-
-
Florida
-
Boca Raton, Florida, United States, 33486
-
Hialeah, Florida, United States, 33012
-
Miami, Florida, United States, 33125
-
-
Illinois
-
Chicago, Illinois, United States, 60640
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48334
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
-
Middleburg Heights, Ohio, United States, 44130
-
-
Pennsylvania
-
Conshohocken, Pennsylvania, United States, 19428
-
Phoenixville, Pennsylvania, United States, 19460
-
-
Texas
-
Bedford, Texas, United States, 76021
-
DeSoto, Texas, United States, 75115
-
Houston, Texas, United States, 77030
-
Houston, Texas, United States, 77008
-
Irving, Texas, United States, 75062
-
San Antonio, Texas, United States, 78229
-
-
Washington
-
Richland, Washington, United States, 99352
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have one of the following clinical diagnoses for at least 3 months prior to screening a) schizophrenia or schizoaffective disorder; b) mood disorder; or c) gastrointestinal disorder (e.g., gastroparesis, gastroesophageal reflux disease)
- Have a clinical diagnosis of neuroleptic-induced tardive dyskinesia for at least 3 months prior to screening.
- Be receiving a stable dose of antipsychotic medication for a minimum of 30 days before study start. Subjects who are not using antipsychotic medication must have stable psychiatric status.
- Have the doses of concurrent medications and the conditions being treated be stable for a minimum of 30 days before study start and be expected to remain stable during the study.
- Subjects of childbearing potential must agree to use hormonal or two forms of nonhormonal birth control during the study.
- Female subjects must not be pregnant.
- Be in good general health and expected to complete the clinical study as designed.
- Have a body mass index (BMI) of 18 to 38 kg/m2 (both inclusive).
- Have a negative urine drug screen (negative for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids) at screening and study start, except for any subject receiving a stable dose of benzodiazepine.
- Have a negative alcohol breath test at screening and study start.
Exclusion Criteria:
- Have an active clinically significant unstable medical condition within 1 month (30 days) prior to screening.
- Have a history of substance dependence or substance (drug) or alcohol abuse within the 3 months before study start(nicotine and caffeine dependence are not exclusionary).
- Have a known history of neuroleptic malignant syndrome.
- Have a significant risk of suicidal or violent behavior.
- Receiving any excluded concomitant medication such as reserpine, metoclopramide, stimulants, or tetrabenazine.
- Receiving medication for the treatment of tardive dyskinesia.
- Have a positive human immunodeficiency virus antibody, (HIV-Ab), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody result at screening or have a history of positive result.
- Have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study.
- Have an allergy, hypersensitivity, or intolerance to tetrabenazine.
- Have had previous exposure with NBI-98854.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: NBI-98854
Dose titration to determine a subject's optimal dose in the range of 25 to 75 mg NBI-98854.
Dose titration is performed in increments of 25 mg.
NBI-98854 administered as one (1) 25 mg capsule, two (2) 25 mg capsules, or one (1) 25 mg capsule and one (1) 50 mg capsule by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
|
25 mg capsule
50 mg capsule
|
PLACEBO_COMPARATOR: Placebo
Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6
Time Frame: Baseline and Week 6
|
The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia).
Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7).
The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
|
Baseline and Week 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Global Impression - Global Improvement of TD (CGI-TD) at Week 6
Time Frame: Week 6
|
Clinician's perspective of the participant's overall improvement of TD symptoms over time.
The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).
|
Week 6
|
AIMS Dyskinesia Total Score Change From Baseline at Week 6
Time Frame: Week 6
|
The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia).
Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7).
The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
|
Week 6
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Sajatovic M, Alexopoulos GS, Burke J, Farahmand K, Siegert S. The effects of valbenazine on tardive dyskinesia in older and younger patients. Int J Geriatr Psychiatry. 2020 Jan;35(1):69-79. doi: 10.1002/gps.5218. Epub 2019 Oct 31.
- Grigoriadis DE, Smith E, Hoare SRJ, Madan A, Bozigian H. Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites. J Pharmacol Exp Ther. 2017 Jun;361(3):454-461. doi: 10.1124/jpet.116.239160. Epub 2017 Apr 12.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Movement Disorders
- Dyskinesia, Drug-Induced
- Dyskinesias
- Tardive Dyskinesia
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Adrenergic Uptake Inhibitors
- Tetrabenazine
Other Study ID Numbers
- NBI-98854-1202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tardive Dyskinesia
-
Neurocrine BiosciencesCompletedTardive Dyskinesia (TD)United States, Puerto Rico
-
GGZ CentraalUniversity Medical Center Groningen; Maastricht UniversityTerminatedTardive Dyskinesia | Tardive DystoniaNetherlands
-
Synchroneuron Inc.WithdrawnDrug-induced Tardive DyskinesiaUnited States
-
Centre for Addiction and Mental HealthMerck KGaA, Darmstadt, GermanyTerminatedNeuroleptic-induced Tardive DyskinesiaCanada, India
-
Taoyuan Psychiatric Center, Ministry of Health...Department of HealthCompletedNeuroleptic-Induced Tardive DyskinesiaTaiwan
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Neurocrine BiosciencesCompletedTardive DyskinesiaUnited States
-
Shanghai Mental Health CenterUnknownTardive DyskinesiaChina
-
Neurocrine BiosciencesEvideraUnknownTardive DyskinesiaUnited States
-
Beersheva Mental Health CenterStanley Medical Research InstituteCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States